Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 1 2

Status

Recruiting 3Terminated 1Not yet recruiting 1

Sponsor Class

OTHER 3NIH 2

Study Type

Interventional 4Observational 1

Sponsor

Cancer Type

Sarcoma 5CNS 5

Conditions

Lung Neoplasms 84Prostatic Neoplasms 73Leukemia, Myeloid, Acute 72Carcinoma, Non-Small-Cell Lung 61Neoplasm Metastasis 60Breast Neoplasms 56Multiple Myeloma 47Colorectal Neoplasms 46Pancreatic Neoplasms 42Carcinoma, Renal Cell 36Myelodysplastic Syndromes 35Melanoma 34Ovarian Neoplasms 33Leukemia, Lymphocytic, Chronic, B-Cell 30Triple Negative Breast Neoplasms 28Glioblastoma 28Precursor Cell Lymphoblastic Leukemia-Lymphoma 27Lymphoma, Large B-Cell, Diffuse 26Urinary Bladder Neoplasms 25Lymphoma 23Squamous Cell Carcinoma of Head and Neck 22Burkitt Lymphoma 22Fallopian Tube Neoplasms 21Glioma 20Carcinoma, Hepatocellular 20Brain Neoplasms 18Mouth Neoplasms 17Lymphoma, Non-Hodgkin 17Leukemia, Biphenotypic, Acute 17Endometrial Neoplasms 17

Interventions

Temozolomide 131Radiotherapy 87Bevacizumab 43Radiation 31Carmustine 29Magnetic Resonance Spectroscopy 22Irinotecan 22Erlotinib Hydrochloride 22Chemotherapy, Adjuvant 20Surgical Procedures, Operative 15O(6)-benzylguanine 15Carboplatin 14Radiotherapy, Intensity-Modulated 13Radiotherapy, Conformal 13sargramostim 12Sirolimus 9Imatinib Mesylate 9Filgrastim 9Drug Therapy 9temsirolimus 8Thalidomide 8Sorafenib 8Radiosurgery 8pembrolizumab 7motexafin gadolinium 7aldesleukin 7Vorinostat 7Procarbazine 7Gene Expression Profiling 7Gefitinib 7

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

5 trials
RecentStart dateEnrollment
Gliosarcoma × Specimen Handling × Clear all
NCT07422363 2026-05-13

Testing the Combination of Anti-cancer Drugs Actimab-A and Cemiplimab (REGN2810) to Improve Outcomes for Patients With Recurrent Glioblastoma

National Cancer Institute (NCI)

Phase 1 Not yet recruiting
30 enrolled
CNSSarcoma

Glioblastoma, Gliosarcoma

NCT07301268 2026-04-08

GI-102 Alone or With Pembrolizumab Before Surgery for Treatment of Recurrent or Progressive IDH Wildtype Glioblastoma and IDH Mutated Grade 4 Astrocytoma

Mayo Clinic

Phase 2 Recruiting
36 enrolled
CNSSarcoma

Astrocytoma, Glioblastoma, Gliosarcoma

NCT05756985 2026-02-04

Improving Understanding of Glioblastoma Through Preservation of Biologically Active Brain Tissue

Baptist Health South Florida

Recruiting
120 enrolled
CNSSarcoma

Glioblastoma, Gliosarcoma

NCT05465954 2026-01-12

Efineptakin Alfa and Pembrolizumab for the Treatment of Recurrent Glioblastoma

Mayo Clinic

Phase 2 Recruiting
54 enrolled
CNSSarcoma

Glioblastoma, Gliosarcoma

NCT03107780 2025-11-13

Testing the Ability of AMG 232 (KRT 232) to Get Into the Tumor in Patients With Brain Cancer

National Cancer Institute (NCI)

Phase 1 Terminated
32 enrolled
CNSSarcoma

Glioblastoma, Gliosarcoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡